COVID-19 rapid guideline: managing COVID-19 - NICE guideline [NG191]

This guideline covers the management of COVID-19 for children, young people and adults in all care settings. It brings together our existing recommendations on managing COVID-19 so that healthcare staff and those planning and delivering services can find and use them more easily. The guideline includes new recommendations on therapeutics, and we will update the guideline further as new evidence emerges.

The guideline updates and replaces our COVID-19 rapid guidelines on critical care in adults, managing symptoms (including at the end of life) in the community, managing suspected or confirmed pneumonia in adults in the community, acute myocardial injury, antibiotics for pneumonia in adults in hospital, acute kidney injury in hospital, and reducing the risk of venous thromboembolism in over 16s with COVID-19.

We have published this guideline in MAGICapp, a global evidence ecosystem already being used by key partners such as the Australian Taskforce for COVID-19 and the World Health Organisation. The MAGICapp platform allows the efficient sharing of evidence between guideline developers from around the world. This means NICE can develop and update its COVID-19 guidance more quickly and efficiently as new evidence is assessed. We collaborated with the Australian National COVID-19 Clinical Evidence Taskforce during development of the guideline, and acknowledge their contribution to identifying and reviewing the evidence for therapeutics.

Read the full guidelines here